April 6, 2022 -- Bruker has acquired biopharma solutions provider Optimal Industrial Automation and Technologies. The company said that the acquisition will strengthen it as a key software and solutions provider for small molecule, biologics, and new drug modalities pharma companies.
Optimal is a pioneer in pharma and biopharma process analytical technology (PAT), pharma manufacturing automation, and quality assurance software, according to a press release from both companies. With these biopharma tools, Bruker will be able to bring efficacious and safe medicines to market in short periods, the company said.
Financial details of the acquisition were not disclosed. Optimal's 2022 revenue is expected to be approximately $10 million, and Optimal's revenue growth rate and operating margins are projected to be accretive to Bruker in 2023 and beyond, according to the release.